标题
A safety update on sodium glucose co‐transporter 2 inhibitors
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 21, Issue S2, Pages 34-42
出版商
Wiley
发表日期
2019-05-13
DOI
10.1111/dom.13611
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- Initiation of dapagliflozin and treatment-emergent fractures
- (2018) Konstantinos A. Toulis et al. DIABETES OBESITY & METABOLISM
- Empagliflozin: A Review in Type 2 Diabetes
- (2018) James E. Frampton DRUGS
- Adverse effects of SGLT2 inhibitors on bone health
- (2018) Jenny E. Blau et al. Nature Reviews Nephrology
- Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
- (2018) Ken Yan Thong et al. Primary Care Diabetes
- Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
- (2018) Niklas Schmedt et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
- (2018) Ghadeer K. Dawwas et al. DIABETES OBESITY & METABOLISM
- Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study
- (2018) Chintan V. Dave et al. DIABETES OBESITY & METABOLISM
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis
- (2018) Sruthi Adimadhyam et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database
- (2017) A. Perlman et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
- (2017) Francesca Cinti et al. Drug Design Development and Therapy
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists
- (2016) David Z.I. Cherney et al. CIRCULATION
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
- (2016) Biff F. Palmer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study
- (2015) Tim Heise et al. CLINICAL THERAPEUTICS
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoglycemia in Patients with Diabetes and Renal Disease
- (2015) Mazen Alsahli et al. Journal of Clinical Medicine
- A Review on the Relationship between SGLT2 Inhibitors and Cancer
- (2014) Hao-Wen Lin et al. International Journal of Endocrinology
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Genital Mycotic Infections in Patients With Diabetes
- (2013) Paul Nyirjesy et al. POSTGRADUATE MEDICINE
- Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
- (2012) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search